Neurocrine Biosciences Inc

NBIX has pulled back into the 150–155 consolidation after a sharp sell-off and is now deeply oversold near its 200-day SMA support. Under mean-reversion eligibility, the medium-term bias flips bullish, but short-term timing remains unfavorable with price below declining EMAs. The long-term uptrend above the rising 200-day SMA is intact, so patience is required to stalk defined-risk bounces around the 147–150 support zone.

• ↑Q1 2026 net product sales >$800M (+44% YoY); Ingreza sales $657M (+20%).
• ↑Upgraded Ingreza guidance to $2.825–$2.875B; Chronicity Q2 revenue $184M with 15% penetration.
• ↓Ingreza pricing expected to decline 5% in 2026, squeezing margins.